“IsoRay Intends to Vigorously Defend Litigation” Richland, WA (June 23, 2015) – IsoRay, Inc.
June 30, 2015 – Outlining possible business risk thesis in reference to The Street, Inc. in comment form in response to Seeking Alpha article published the same day -TheStreet: Still Below $2, And Still Interesting
June 22, 2015 – Open Letter to Board of Directors, The Street, Inc. – RE: Possible Fiduciary Breach of Duty of Loyalty & Duty of Care by The Board of Directors of the Street, Inc., a publicly traded corporation
June 17, 2015 – Open Letter to Ms. Edith Ramirez, Chairwoman, Federal Trade Commission – Re: The Street, Inc. possible Nationwide Advertising Fraud & Deception possibly causing irreparable harm against innumerable U.S. Citizens and IsoRay, Inc. a company domiciled in Washington State
June 9, 2015 – Open Letter to The Street, Inc., CEO & Chairman, Ms Elisabeth H DeMarse – Re: Failure to retract possibly false and slanderous statements made by Mr. Adam Feurestein and TheStreet.com within an article published on May 21, 2015 entitled:’ IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price ‘
“Conclusion WR, WR+ Cs-131, or SBRT are all excellent treatment options for patients with early-stage non-small cell lung cancer that are not candidates for lobectomy. For high risk WRs, we favor use of Cesim-131 brachytherapy.” ( May 19, 2015) Bhupesh Parashar M.D., Jeffery Port M.D., Shruthi Arora M.D., Paul Christos Dr.P.H. M.S., Samuel Trichter M.D., Dattatreyudi Nori M.D., A. Griella Wernicki M.D.